Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.48
Dollar change
-0.19
Percentage change
-5.18
%
Index- P/E- EPS (ttm)-0.07 Insider Own40.77% Shs Outstand74.98M Perf Week8.75%
Market Cap262.08M Forward P/E60.52 EPS next Y0.06 Insider Trans0.02% Shs Float44.60M Perf Month102.33%
Income-4.94M PEG- EPS next Q-0.02 Inst Own15.50% Short Float2.63% Perf Quarter140.00%
Sales83.57M P/S3.14 EPS this Y78.57% Inst Trans-19.26% Short Ratio5.48 Perf Half Y140.00%
Book/sh0.38 P/B9.17 EPS next Y483.33% ROA-9.06% Short Interest1.17M Perf Year124.52%
Cash/sh0.36 P/C9.59 EPS next 5Y- ROE-17.29% 52W Range1.25 - 4.06 Perf YTD143.36%
Dividend Est.- P/FCF38.04 EPS past 5Y35.83% ROI-15.91% 52W High-14.28% Beta1.99
Dividend TTM- Quick Ratio1.70 Sales past 5Y22.27% Gross Margin60.76% 52W Low178.40% ATR (14)0.35
Dividend Ex-Date- Current Ratio2.40 EPS Y/Y TTM72.60% Oper. Margin-3.95% RSI (14)71.71 Volatility16.03% 13.97%
Employees106 Debt/Eq0.12 Sales Y/Y TTM15.99% Profit Margin-5.91% Recom1.00 Target Price5.91
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q107.81% Payout- Rel Volume2.27 Prev Close3.67
Sales Surprise1.84% EPS Surprise100.00% Sales Q/Q0.95% EarningsMar 06 AMC Avg Volume214.23K Price3.48
SMA2042.62% SMA5083.64% SMA200118.46% Trades Volume486,389 Change-5.18%
Date Action Analyst Rating Change Price Target Change
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
Mar-06-24 09:53PM
04:04PM Loading…
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
06:33PM Loading…
Nov-08-23 06:33PM
04:48PM
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
Aug-09-23 05:40PM
04:37PM
04:02PM
Aug-08-23 08:34AM
Aug-07-23 08:32AM
08:02AM Loading…
Aug-02-23 08:02AM
Jul-18-23 08:32AM
Jun-16-23 08:32AM
Jun-08-23 08:19AM
May-30-23 08:34AM
May-11-23 08:34AM
May-10-23 05:35PM
04:32PM
04:02PM
May-02-23 08:32AM
06:31AM
Apr-12-23 01:04PM
Mar-27-23 06:43AM
Mar-10-23 05:23AM
02:28AM
Mar-09-23 09:06AM
Mar-08-23 06:25PM
04:02PM
Mar-06-23 08:34AM
Mar-02-23 10:00AM
Mar-01-23 10:00AM
Feb-27-23 08:32AM
Feb-22-23 08:34AM
Feb-21-23 08:32AM
Jan-31-23 08:32AM
Jan-17-23 08:28AM
Jan-15-23 08:52AM
Jan-12-23 08:34AM
Jan-05-23 08:33AM
Dec-27-22 08:30AM
Dec-19-22 09:35AM
Dec-16-22 09:35AM
Nov-11-22 08:12AM
Nov-09-22 05:02AM
Nov-02-22 05:35PM
04:02PM
11:40AM
Oct-26-22 08:35AM
Oct-24-22 08:32AM
Oct-11-22 07:32AM
Oct-06-22 08:53AM
Oct-04-22 06:32AM
Oct-03-22 07:30AM
Sep-19-22 06:05PM
Sep-01-22 06:32AM
Aug-29-22 03:07PM
Aug-24-22 09:00AM
09:00AM
Aug-15-22 06:34AM
Aug-10-22 05:45PM
04:02PM
Aug-08-22 09:41AM
Aug-02-22 06:32AM
Jul-10-22 09:57AM
Jul-07-22 06:32AM
Jun-22-22 06:07AM
Jun-15-22 06:34AM
Jun-10-22 06:32AM
Jun-07-22 01:33PM
Jun-02-22 06:34AM
Jun-01-22 06:32AM
May-22-22 08:17AM
May-20-22 10:02AM
May-19-22 04:34PM
May-17-22 08:27AM
06:34AM
May-12-22 05:35PM
04:03PM
May-09-22 08:25AM
May-05-22 08:35PM
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gerber BriannaChief Financial OfficerDec 01 '23Buy1.415,0007,05027,436Dec 04 04:12 PM
Jaksch Frank L JrDirectorJun 12 '23Buy1.697,00011,830231,339Jun 13 04:50 PM
Fried Robert NChief Executive OfficerMay 31 '23Buy1.427,0009,94095,001Jun 01 04:27 PM
Rubin Steven DDirectorMay 25 '23Buy1.467,00010,2207,000May 30 04:13 PM